IL290626A - Tetracyclic compounds and their salts, compositions, and methods for their use - Google Patents
Tetracyclic compounds and their salts, compositions, and methods for their useInfo
- Publication number
- IL290626A IL290626A IL290626A IL29062622A IL290626A IL 290626 A IL290626 A IL 290626A IL 290626 A IL290626 A IL 290626A IL 29062622 A IL29062622 A IL 29062622A IL 290626 A IL290626 A IL 290626A
- Authority
- IL
- Israel
- Prior art keywords
- salts
- compositions
- methods
- tetracyclic compounds
- tetracyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886621P | 2019-08-14 | 2019-08-14 | |
| US201962946774P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/046329 WO2021030671A1 (en) | 2019-08-14 | 2020-08-14 | Tetracyclic compounds and their salts, compositions, and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290626A true IL290626A (en) | 2022-04-01 |
Family
ID=74568302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290626A IL290626A (en) | 2019-08-14 | 2022-02-14 | Tetracyclic compounds and their salts, compositions, and methods for their use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210046071A1 (https=) |
| EP (1) | EP4013421A4 (https=) |
| JP (1) | JP7566010B2 (https=) |
| KR (1) | KR20220130085A (https=) |
| CN (1) | CN114599368A (https=) |
| AU (1) | AU2020328590B2 (https=) |
| BR (1) | BR112022002784A2 (https=) |
| CA (1) | CA3151112A1 (https=) |
| IL (1) | IL290626A (https=) |
| PH (1) | PH12022550360A1 (https=) |
| TW (1) | TW202114694A (https=) |
| WO (1) | WO2021030671A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7017509B2 (ja) | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| CN112334133A (zh) | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
| CN114409681A (zh) * | 2022-03-18 | 2022-04-29 | 信义核新(北京)生物科技有限公司 | 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7928100B2 (en) * | 2007-10-05 | 2011-04-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
| ES2754207T3 (es) * | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
| JP7017509B2 (ja) * | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| US9957282B2 (en) * | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| JP2018537486A (ja) * | 2015-12-14 | 2018-12-20 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びその塩の結晶形 |
| CN112334133A (zh) * | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
-
2020
- 2020-08-14 EP EP20851932.2A patent/EP4013421A4/en active Pending
- 2020-08-14 PH PH1/2022/550360A patent/PH12022550360A1/en unknown
- 2020-08-14 CA CA3151112A patent/CA3151112A1/en active Pending
- 2020-08-14 TW TW109127804A patent/TW202114694A/zh unknown
- 2020-08-14 CN CN202080069508.0A patent/CN114599368A/zh active Pending
- 2020-08-14 BR BR112022002784A patent/BR112022002784A2/pt not_active Application Discontinuation
- 2020-08-14 AU AU2020328590A patent/AU2020328590B2/en active Active
- 2020-08-14 JP JP2022509131A patent/JP7566010B2/ja active Active
- 2020-08-14 KR KR1020227008247A patent/KR20220130085A/ko not_active Withdrawn
- 2020-08-14 US US16/993,840 patent/US20210046071A1/en active Pending
- 2020-08-14 WO PCT/US2020/046329 patent/WO2021030671A1/en not_active Ceased
-
2022
- 2022-02-14 IL IL290626A patent/IL290626A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021030671A1 (en) | 2021-02-18 |
| JP2022544559A (ja) | 2022-10-19 |
| US20210046071A1 (en) | 2021-02-18 |
| JP7566010B2 (ja) | 2024-10-11 |
| AU2020328590A1 (en) | 2022-03-10 |
| PH12022550360A1 (en) | 2023-02-27 |
| KR20220130085A (ko) | 2022-09-26 |
| AU2020328590B2 (en) | 2026-03-26 |
| EP4013421A1 (en) | 2022-06-22 |
| EP4013421A4 (en) | 2023-08-23 |
| TW202114694A (zh) | 2021-04-16 |
| CA3151112A1 (en) | 2021-02-18 |
| CN114599368A (zh) | 2022-06-07 |
| BR112022002784A2 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290276A (en) | Tetracyclic compound, preparation method and use thereof | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| PL3958977T3 (pl) | Pochodne kamptotecyny | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| DK3768674T3 (da) | Aminopyrimidinderivater som ctps1-hæmmere | |
| MX377277B (es) | Derivados de fenoximetilo. | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| DK3294738T3 (da) | Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus | |
| EP3877381A4 (en) | BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | |
| DK3684333T3 (da) | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil | |
| EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| DK3350163T3 (da) | Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation | |
| PT3837256T (pt) | Compostos e composições de ureia como inibidores de smarca2/brm-atpase | |
| EP3989952A4 (en) | Cbd composition | |
| DK3766885T3 (da) | Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer | |
| DK3762368T3 (da) | Aminopyrazindiolforbindelser som pi3k-y-inhibitorer | |
| DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
| DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
| EP3967726A4 (en) | Curable composition | |
| IL290626A (en) | Tetracyclic compounds and their salts, compositions, and methods for their use | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3896109A4 (en) | CURABLE COMPOSITION | |
| EP3871694A4 (en) | COMPOSITION | |
| MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| DK3204380T3 (da) | Hidtil ukendte aminopyridinforbindelser, der er anvendelige som hæmmere af proteinprenylering |